Kane Biotech

Novel wound care to disrupt biofilms and transform healing outcomes

October 2025

Dr. Robert Huizinga
Interim Chief Executive Officer

Forward-Looking Statements

This presentation contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements.

Such risks and uncertainties include, but are not limited to, the availability of funds and resources to pursue R&D activities, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in its specific industry, and uncertainties related to the regulatory process and general changes in economic conditions.

Investors should consult the Company's ongoing filings which are available on SEDAR for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements nor does the Company undertake to update or revise any these forward-looking statements contained herein.

Kane Biotech

- Publicly traded small-cap biotech company: TSX-V: KNE | US OTC
- Based in Winnipeg, Canada – headquartered at the University of Manitoba Smartpark Innovation Hub
- Leader in anti-biofilm technologies
- FDA/Health Canada-cleared products
- Licensing-based growth model designed to drive partnerships and scale
- Experienced Leadership Team and Board of Directors

The Problem With Wounds

Biofilms are one of the main contributors to antibiotic resistance [1]

Whether from burns, surgery or diabetes, wound care solutions require treating **both bacteria** and **biofilms** [2-6]

What are Biofilms?

- A bacterial mechanism creating a matrix that protects the cells and reduces their metabolic activity

- Biofilms make bacteria up to 1,000 times more resistant to antibiotics, antimicrobial agents, disinfectants and the host immune system
  - Requires physical or chemical disruption before bacterial killing is effective

- ≥ 70 % of burn and ≥ 80 % chronic wounds have a biofilm layer[1,7]



revyve®: The Triple Threat for Wounds

Proprietary formula fights biofilms and other factors in wound nonhealing:

1. Surfactant gel supports autolytic debridement
2. Cationic antimicrobial kills bacteria for up to 7 days without antibiotics
3. coactiv+™ breaks down biofilm and reduces elevated protease activity

7 Day Antibiotic-Resistant Biofilm Activity

S. aureus



P. aeruginosa



Multi Pathogen Activity With Colony Biofilm Model



3 Significant Markets for our Products

Proprietary Technology

Chronic Wounds, DFU, VSU

OTC Retail Markets

Inpatient burn/wound care

Wound Gel: Chronic Wounds and OTC

- Treats multispecies bacteria and biofilms
- Day 1 treatment that is reimbursable by Medicare – Medicaid
- No Restriction on length of use
- Can be used with multiple dressing types
- FDA 510(k) Cleared

Wound Spray: Burn/Wound Care

- Same properties as our Wound Gel
- Non-aerosol spray strongly adheres to and stays in place on wounds
- Designed for painless delivery
- Easy removal
- FDA 510(k) Cleared

Easy to Apply – Rinses off with cool water

- At cooler temperatures, revyve™ liquifies to completely fill and conform to 3D contours of the wound
- Optimizes application for deep cavity and complex wounds
- Aids with easy removal when washing off with cool water

REVYVE™ TRANSITION POINT FOR DESIRED STATE

- Heat-activated by body temperature, revyve™ gel thickens further to strongly adhere to the wound
- Maintains thickness throughout use keeping gel in place on the wound
- Maintains optimal moist wound environment without causing maceration

Convert non-healing wounds to healing wounds[8]

Day 1

Day 29

Day 53

Day 97

A 52 year-old male with diabetic foot ulcer[8]. Multiple unsuccessful treatments prior

After the End of the Study[8]

A 52 year-old male with diabetic foot ulcer[8]. Multiple unsuccessful treatments prior

Clinical Value

Clinically Valuable for Patients

- Easy to apply & remove
  - Covers complex wound geometry
  - Non-contact = reduced pain (spray)
  - Thermoreversible
- Targets bacteria & biofilms
  - Effective against antimicrobial-resistant strains
  - May reduce need for antibiotics

Financially Valuable for Practices

- DME distribution
  - Ease of patient and provider access
- Supports healthy wound bed
  - May improve efficacy of tissue products
  - May reduce need for costly advanced wound care products
- Compatible with current practice
  - No extensive training required
  - Works with most dressings

Intellectual Property

- revyve composition patent (March 2034).
- Bag-on-valve gel spray patent (Published July 31, 2025. Review anticipated in October).
- A total of 54 patents and patents pending.

Wound & Burn Centers Involved in Case Series

- Mount Sanai West Hospital (NY)
- University of North Carolina (NC)
- Raleigh Foot and Ankle Center (NC)
- Foot & Ankle Institute of the Carolinas
- St. Louis Foot and Ankle LCC (MO)
- Northwell Health (NY)
- Georgiades Surgical Associates (PA)
- The WISH clinic (CO)
- Burn and Reconstructive Centers of America (GA)

- Each case series is approximately 5 patients
- Individual case series to be presented at regional meetings
- Combined analysis of cases to be presented in 2026

Summary

- FDA/Health Canada-cleared products
- US Clinical Case Series Drawing to a Close with Early Positive Results
- Commercialization-Ready
- Distribution Discussions Underway

Board of Directors

Philip Renaud, BA: Board Chair
Chairman, CEO and President of Redecam Group.

John Coleman, PhD: Lead Independent Director
President & CEO of Avivo Biomedical Inc. Co-founder Anandia Labs in 2013.

Anne Greven, MBA: Director. Chair of Nomination & Governance Committee
Managing Director & Head of Loan Distribution Group at ING Capital LLC in NA.

David Kideckel, MBA PhD: Director
CFO and Board Director at Rakovina Therapeutics

Shameze Rampertab CPA, CA, MBA: Director. Chair of Audit Committee
Exec VP and CFO for Asensus Surgical, Inc.

Robert Huizinga PhD RN: Director
Interim CEO of Kane Biotech Inc. Co-founder Aurinia Pharmaceuticals in 2013.

Management

- **Robert Huizinga, PhD RN**
  - Interim Chief Executive Officer

- **Ray Dupuis, CPA, MBA**
  - Chief Financial Officer

- **Lori Christofalos, BSc.**
  - Chief Quality Officer

Let’s Connect

Robert B. Huizinga PhD RN
Interim CEO
Kane Biotech

rhuizinga@kanebiotech.com

Kane Biotech

Novel wound care to disrupt biofilms and transform healing outcomes

Thank-you

Footnotes

1. Malone, M., Bjarnsholt, T., McBain, A.J, James GA, Stoodley P, Leaper D, Tachi M, Schultz G, Swanson T, Wolcott RD. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. *Journal of Wound Care*. 2017 Jan 2;26(1):20–5
2. James GA, Swogger E, Wolcott R, Pulcini E, Secor P, Sestrich J, Costerton JW, Stewart PS (2008) *Wound Repair Regen* 16:37–44
3. Nussbaum, Samuel R. et al. (2018), *Value in Health*, Volume 21, Issue 1, 27 - 32
4. Ivanko, et al. (2024), *Journal of Burn Care & Research*, Volume 45, Issue 5: 1095–1097
5. Linder, J. (2025). Burn statistics. Gitnux Burn Statistics Report 2025
6. MRG Insights. Source: US and Global Wound Dressing Data 2022
7. Goswami, A.G., Basu, S., Banerjee, T. et al. (2023) Biofilm and wound healing: from bench to bedside. *Eur J Med Res* **28**, 157 (2023)
8. Kane Biotech Inc., Data on File. R. Pointer et al. (2025) *NSWOCC 2025*